Latest Advances in Lung Cancer Research

Researchers explain why there is an increase in never-smokers getting lung cancer – looking at risk factors contributing to the rise and the early symptoms.

Dr. Kathryn Gold discusses the latest insights on small-cell lung cancer guidelines from the National Comprehensive Cancer Network.

Requires Subscription now to view full article

How cancer patients are responding to the COVID vaccine. Results show poor response after first dose and empahsize need to avoid delay between doses.

Seeking to expand targeted therapy for lung cancer, Dr. Alice Berger, a recipient of a LCFA lung cancer research grant, has also received a NIH MERIT Award.

Latest in depth analysis and recommendations for lung cancer screening from the United States Preventive Services Task Force

Sotorasib drug shows meaningful benefits clincally with advanced KRAS G12C mutation in non-small cell lung cancer patients.

BAD LINK – see if the article is elsewhere

Lung cancer care disparities: An in depth analysis of racial disparity and inclusivity in lung cancer heath care, research, and community buidling.

Lorlatinib approved for ALK-Positive NSCLC. The FDA expands approval of Lorlatinib for frontline treatment of ALK+ lung cancer patients.

Research shows using both immunotherapy and chemotherapy for treatment doubles survival among those diagnosed with lung cancer.

KRAS mutation, previously seen as “undruggable” sees promise for new therapies through improbable targets for lung cancer.